Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,361 active trials259 approved drugs3,860 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,753 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05128734 | Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) | not yet recruiting | Phase 2 | 40 | AHS Cancer Control AlbertaOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT07281209 | A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 40 | Shanghai Chest HospitalOTHER | 0 | Dec 15, 2025 |
| NCT07282197 | Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019 | not yet recruiting | Phase 2 | 40 | Peking University First HospitalOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT07282509 | Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer | not yet recruiting | Phase 1 / Phase 2 | 116 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Dec 15, 2025 | clinicaltrials |
| NCT07283198 | A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 160 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 0 | Dec 15, 2025 | clinicaltrials |
| NCT07279584 | Golidocitinib Combined With GemOx in RR PTCL | not yet recruiting | Phase 2 | 31 | Ruijin HospitalOTHER | 0 | Dec 12, 2025 | clinicaltrials |
| NCT05522491 | Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer | not yet recruiting | Phase 2 | 30 | Hebei Medical University Fourth HospitalOTHER | 0 | Dec 11, 2025 | clinicaltrials |
| NCT07276698 | Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma | not yet recruiting | Phase 2 | 39 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Dec 11, 2025 | clinicaltrials |
| NCT07276737 | Preconditioning With a Combination of Thiotepa, Cyclophosphamide, and Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of NK/T-Cell Lymphoma | not yet recruiting | Phase 2 | 37 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Dec 11, 2025 | clinicaltrials |
| NCT07277452 | Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer(NOTABLE-309) | not yet recruiting | Phase 2 | 156 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07277972 | Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy | not yet recruiting | Phase 2 | 36 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Dec 11, 2025 | clinicaltrials |
| NCT07274384 | Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial(HYPERBOLIC) | not yet recruiting | Phase 2 | 74 | Università Vita-Salute San RaffaeleOTHER | 0 | Dec 10, 2025 | clinicaltrials |
| NCT07271602 | A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer. | not yet recruiting | Phase 2 | 104 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Dec 9, 2025 | clinicaltrials |
| NCT07271992 | TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer(TREND-02) | not yet recruiting | Phase 2 | 30 | First Hospital of China Medical UniversityOTHER | 0 | Dec 9, 2025 | clinicaltrials |
| NCT07272291 | A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 48 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Dec 9, 2025 | clinicaltrials |
| NCT07272590 | Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 290 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Dec 9, 2025 | clinicaltrials |
| NCT05106127 | Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem | not yet recruiting | Phase 2 | 28 | Evergreen Therapeutics, Inc.INDUSTRY | 0 | Dec 8, 2025 | clinicaltrials |
| NCT06882174 | This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung Cancer(TIME-NSCLC) | not yet recruiting | Phase 2 | 58 | AHS Cancer Control AlbertaOTHER | 0 | Dec 8, 2025 | clinicaltrials |
| NCT07268677 | A Single-arm Clinical Study Evaluating Pirfenidone and Sintilimab in Combination With Standard Neoadjuvant Chemotherapy for Colorectal Cancer Patients With Peritoneal Metastasis. | not yet recruiting | Phase 2 | 30 | Guoxiang CaiOTHER | 0 | Dec 8, 2025 | clinicaltrials |
| NCT07268794 | CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer(CONVERT-HB1) | not yet recruiting | Phase 2 | 112 | Fudan UniversityOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07269158 | A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer | not yet recruiting | Phase 1 / Phase 2 | 160 | Yonsei UniversityOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07256509 | A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 120 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Dec 5, 2025 | clinicaltrials |
| NCT07267234 | PRaG-1 Plus PRaG Therapy in Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0) | not yet recruiting | Phase 2 | 65 | Second Affiliated Hospital of Soochow UniversityOTHER | 0 | Dec 5, 2025 | clinicaltrials |
| NCT07267338 | Pembrolizumab + MRGOO3 as Neoadjuvant in NPC | not yet recruiting | Phase 2 | 35 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT07264010 | Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study | not yet recruiting | Phase 2 / Phase 3 | 87 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Dec 4, 2025 | clinicaltrials |
| NCT07261098 | The Efficacy and Safety of ARNI on the Outcome of Advanced Lung Cancer With Concurrent Hypertension | not yet recruiting | Phase 2 | 200 | Shanghai Chest HospitalOTHER | 0 | Dec 3, 2025 | clinicaltrials |
| NCT07261592 | Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer | not yet recruiting | Phase 1 / Phase 2 | 29 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07261709 | Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial | not yet recruiting | Phase 2 | 236 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07257718 | The Combined Role of FAPI PET and Liquid Biopsy in the Staging and Clinical Management of Bladder Cancer - FUTURE Trial(FUTURE) | not yet recruiting | Phase 2 | 262 | Chiti ArturoOTHER | 0 | Dec 2, 2025 | clinicaltrials |
| NCT07259122 | A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia(ZBR in WM) | not yet recruiting | Phase 2 | 43 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07259161 | Modified Conditioning Regimen for CML-BP | not yet recruiting | Phase 2 | 40 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Dec 2, 2025 | clinicaltrials |
| NCT07260058 | Immune Cell Therapy for Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 48 | Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.INDUSTRY | 0 | Dec 2, 2025 | clinicaltrials |
| NCT07255612 | Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer) | not yet recruiting | Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07246317 | Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer | not yet recruiting | Phase 2 | 188 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT07254962 | CApecitabine Prior to TUmor Resection in Ent Oncology (CAPTURE)(CAPTURE) | not yet recruiting | Phase 2 | 75 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 0 | Nov 28, 2025 | clinicaltrials |
| NCT06547866 | Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström Macroglobulinemia(WAZABI) | not yet recruiting | Phase 2 | 102 | French Innovative Leukemia OrganisationOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07251062 | A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma. | not yet recruiting | Phase 2 / Phase 3 | 737 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Nov 26, 2025 | clinicaltrials |
| NCT07251829 | Neoadjuvant Embolization and Cytoreduction in Prostate Cancer | not yet recruiting | Phase 2 | 35 | Srinivas RamanOTHER | 0 | Nov 26, 2025 | clinicaltrials |
| NCT07252375 | A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 35 | Fujian Cancer HospitalOTHER_GOV | 0 | Nov 26, 2025 | clinicaltrials |
| NCT05453851 | A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatment of Chronic Pancreatitis and Benign Pancreatic Tumors | not yet recruiting | Phase 1 / Phase 2 | 12 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT06400160 | Clinical Trial of TB511 in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 12 | Twinpig Biolab, Inc.INDUSTRY | 0 | Nov 25, 2025 | clinicaltrials |
| NCT07248020 | A Phase II Single-Arm Study of High-Bioavailability Curcumin as Neoadjuvant Chemoradiotherapy in Mid-to-Low Rectal Cancer: Integrated Clinical and Translational Analysis of Tumor Tissue(BCMRECRAD) | not yet recruiting | Phase 2 | 72 | Chang Gung Memorial HospitalOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07249892 | A Study of BPR-6023021 in Advanced Solid Tumors With Bone Metastases | not yet recruiting | Phase 1 / Phase 2 | 195 | Chengdu Syncor Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07243938 | Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET) | not yet recruiting | Phase 2 | 70 | Tao ZhangOTHER | 0 | Nov 24, 2025 | clinicaltrials |
| NCT07243951 | Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma | not yet recruiting | Phase 2 | 75 | Shanghai Zhongshan HospitalOTHER | 0 | Nov 24, 2025 | clinicaltrials |
| NCT07244380 | Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL. | not yet recruiting | Phase 2 | 38 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 0 | Nov 24, 2025 | clinicaltrials |
| NCT07244926 | Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 31 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07244965 | Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer | not yet recruiting | Phase 2 | 42 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07245901 | Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Nov 24, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Dec 15, 2025source: clinicaltrials